Renovorx closes $11.1 million private placement, providing cash runway into 2026

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds. shaun bagai, chief executive officer of renovorx, stated, “we believe our recent financing achievements mark a critical milestone for renovorx. our.
RNXT Ratings Summary
RNXT Quant Ranking